Article | February 7, 2023

Leveraging A Global Drug Development Program To Ensure Clinical Trial Success

Source: Novotech
GettyImages-1222231706 global drug dev

At the onset of a new era in the drug development industry, biotechnology companies are looking for ways to effectively utilize capital and increase asset valuation in an unstable market. Many companies with early-stage development programs are struggling to thrive in the current environment due to reduced funding opportunities that place a greater burden on clinical development programs to succeed. Expanding globally can help save crucial resources and produce high-quality clinical data. However, a globalized approach takes careful planning to ensure regulatory approval.

Experts recommend early globalization of development assets to leverage unique regional advantages that help accelerate data to its inflection point. For example, a company may opt for indication expansion into a country with high disease prevalence, which can generate global value and conserve resources. Delays in getting into Phase 1 units in the U.S. and Europe have made Asia-Pacific (APAC) countries increasingly attractive destinations for early-phase trials where high-integrity, high-quality Phase 1 opportunities exist. Download for greater insight into how to build a global program, including how to identify global partners with proven track records that can help your therapy reach patients faster.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene